Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Craneware LSE:CRW Crashes 24.89% After FY26 Results and Lower FY27 Revenue Outlook

• Craneware LSE:CRW fell24.89% on 21 September 2026, making it one of the largest decliners in the market snapshot.

Ankur Sharma | 21 September 2026

LSE:EDEN Drops 9.52%: What Is Driving Eden Research Shares Lower on 21 September 2026?

Eden Research Plc LSE:EDEN came under renewed selling pressure on21 September 2026, falling9.52% to 1.90p. The move follows a volatile period for the shares, with the stock having closed at 2.10p on 18 September after gaining 5.00% during that session.

Ankur Sharma | 21 September 2026

LSE:PRM Drops 14.86% as Investors Digest H1 Results, Cash Position and Growth Outlook

• The fall comes only days after the company released its H1 2026 results, giving investors fresh information about revenue, cash resources, costs and the pace of its commercial expansion.

Ankur Sharma | 21 September 2026

Provexis LSE:PXS Falls 11.98% as Investors Watch Fruitflow Sales, China Expansion and FY26 Results

• The company remains focused on the commercialisation of its patentedFruitflowtomato extract technology, which is used in food, beverage and dietary supplement applications.

Ankur Sharma | 21 September 2026

Verici Dx Shares Fall 11.11%: Why Is LSE:VRCI Under Pressure Despite a New Q4 Test Launch?

• The decline occurred on the same day that Verici Dx announced the plannedQ4 2026 launch of TranscripTx, a new genetic test designed specifically for the transplant community.

Ankur Sharma | 21 September 2026

What Could Drug Pipeline Milestones Mean for FTSE 100 Stock AstraZeneca (LSE:AZN)?

AstraZeneca is one of the world's largest research-based pharmaceutical companies. Its portfolio spans oncology, rare disease and a biopharmaceuticals division that covers cardiovascular, renal and metabolic medicines alongside respiratory and immunology. The scale is now considerable. Total revenue reached $30.7bn in the six months …

Ankur Sharma | 21 September 2026

Is Oxford Biomedica's CDMO Pivot About to Pay Off in a Big Way?

Oxford Biomedica plc shares rose 1.97% today, based on the supplied market data. The move comes amid ongoing corporate activity, including a confirmed unsolicited cash offer from funds managed by EQT for the entire company, alongside continued strong underlying operational execution.

Divya Sood | 21 September 2026

Could Beacon Therapeutics Be the Catalyst That Reshapes Syncona's Story?

Syncona Limited shares rose 6.45% today, based on the supplied market data. The move comes as the life science investor continues to progress toward a series of clinical value-inflection points it has flagged for calendar year 2026.

Divya Sood | 21 September 2026

How Could NHS Waiting Lists Shape FTSE AIM All-Share Stock One Health Group (LSE:OHGR)?

The full-year results for the year to 31 March 2026 continued a run of expansion.Revenuerose 11% to £31.6m, adjusted EBITDA increased 28% to £2.6m, and the company ended the year with cash of £11.1m, proposing aDividendof 6.3p, according to its reporting. This marked a …

Divya Sood | 21 September 2026

What Could Drug Pipeline Milestones Mean for FTSE 100 Stock AstraZeneca (LSE:AZN)?

AstraZeneca is one of the world's largest research-based pharmaceutical companies. Its portfolio spans oncology, rare disease and a biopharmaceuticals division that covers cardiovascular, renal and metabolic medicines alongside respiratory and immunology. The scale is now considerable. Total revenue reached $30.7bn in the six months …

Ankur Sharma | 21 September 2026
Support

Hi! How can we help you today?

Loading…